[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"University of Alberta\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":669},{"pageToken":4,"total":5,"offset":6,"count":7,"results":8},null,168,0,25,[9,55,82,102,129,148,170,205,234,258,295,319,345,365,390,413,453,475,499,518,548,571,596,619,645],{"id":10,"slug":11,"hasResults":12,"nctId":13,"briefTitle":14,"officialTitle":15,"acronym":4,"eligibilityCriteria":16,"healthyVolunteers":17,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":29,"overallStatus":42,"whyStopped":4,"lastUpdateSubmitDate":43,"lastUpdatePostDateStruct":44,"startDateStruct":47,"completionDateStruct":49,"leadSponsor":51,"locationsCount":54},"100644083","evaluating-ai-for-the-translation-of-km-resources-100644083",false,"NCT07666399","Evaluating AI for the Translation of KM Resources","Evaluating Artificial Intelligence for Language Translation of Health-related Knowledge Mobilization Resources: A Randomized Controlled Trial and Qualitative Study","Inclusion Criteria:\n\n* Adult (18 years or older)\n* Currently a parent or familial caregiver of a child (\\\u003C18 years)\n* Lives in Canada\n* First language (native language, language learned from birth) is Mandarin, Punjabi, Tagalog, or Urdu\n* Able to communicate (read and respond to questions) in English\n* Access to an electronic device (e.g., computer), Internet, and email\n\nExclusion Criteria:\n\n* Under \\\u003C18 years\n* Does not currently identify as a parent or familial caregiver of a child (\\\u003C18 years)\n* Does not live in Canada\n* Does not identify their first language as Mandarin, Punjabi, Tagalog, or Urdu\n* Unable to communicate (read and respond to questions) in English\n* No access to an electronic device (e.g., computer), Internet, or email",true,"ALL","18 Years",{"count":21,"type":22},576,"ESTIMATED","INTERVENTIONAL",[25],"NA","Knowledge mobilization resources for parents provide information to help make health decisions for their children. These resources can include videos, infographics, and plain language summaries. They are often created in English. This can make them hard to understand for people whose first language is not English. Translating these resources into other languages may be helpful. However, professional translation can take time and be expensive.\n\nThe study will compare a resource that is in English with the same resource translated into another language. The investigators will use both high and low resource languages commonly spoken in Alberta: Mandarin, Punjabi, Tagalog, Urdu. Parents who speak these languages will be asked to answer questions about how easy it is to understand and use the information. The investigators will also see if artificial intelligence can be used to translate the resource. To do this, parents will be asked to look at a resource that was translated by a professional and the same resource that was translated using artificial intelligence. Then, parents will answer questions about how clear the translations are. Parents will be asked to participate in the study using the internet. They will answer questions using an online questionnaire. Parents will also be asked if they are interested in taking part in an online interview. This will help us understand their thoughts about the resources in more detail. The plan is to involve 576 parents with 144 parents per language group.\n\nThis project will help to better understand whether parents prefer a resource in their own language compared to an English version. It will also help to understand whether artificial intelligence can be used to translate resources so that they are easier for parents to access. This work is very important so that all parents and their children have access to high quality health information. This can help all families make the best decisions for their children's health.",[28],"Communication Research",[30,31,32,33,34,35,36,37,38,39,40,41],"Knowledge Mobilization","Artificial Intelligence","Linguistic Translation","Cultural Diversity","ChatGPT","Health Equity","Parents","Emergency Department","Tagalog","Punjabi","Mandarin","Urdu","NOT_YET_RECRUITING","2026-06-29",{"date":45,"type":46},"2026-07-01","ACTUAL",{"date":48,"type":22},"2026-09",{"date":50,"type":22},"2027-09",{"name":52,"class":53},"University of Alberta","OTHER",1,{"id":56,"slug":57,"hasResults":12,"nctId":58,"briefTitle":59,"officialTitle":60,"acronym":4,"eligibilityCriteria":61,"healthyVolunteers":12,"sex":18,"minAge":62,"maxAge":4,"enrollmentInfo":63,"targetDuration":4,"studyType":23,"phases":65,"briefSummary":66,"conditions":67,"keywords":71,"overallStatus":75,"whyStopped":4,"lastUpdateSubmitDate":43,"lastUpdatePostDateStruct":76,"startDateStruct":77,"completionDateStruct":79,"leadSponsor":81,"locationsCount":54},"100606935","connecting-today-to-combat-social-isolation-and-loneliness-100606935","NCT07182019","Connecting Today to Combat Social Isolation and Loneliness","Connecting Today to Combat Social Isolation and Loneliness: An Evaluation of a Remote Visiting Program for Care Home Residents Living With Dementia","Inclusion Criteria:\n\nResidents:\n\n* are at least 65 years old\n* are diagnosed with any type of dementia\n* have a Cognitive Performance Score (CPS) indicating moderate to severe impairment (CPS 3-6).\n* to participate, residents must also have people that self identify as a family member or friend of the person with dementia.\n\nRemote visitors:\n\n* are people that self-identify as a family member or friend of the person with dementia\n* are people with whom the person with dementia desires contact\n* are 18 or older\n* understand and speak English.\n\nExclusion Criteria:\n\n* All remote visitors are required to understand and speak English as this is necessary for the facilitator to support the call and for data to be collected.","65 Years",{"count":64,"type":22},320,[25],"The investigators developed Connecting Today, a feasible and highly acceptable remote visiting program that can support care home residents living with moderate to severe dementia to have video calls with their family members, friends, or care partners. The investigators will recruit 80 residents from 4 care homes, and their family members, friends, or care partners. All participants will be offered 60 minutes of Connecting Today per week for 6 weeks (in either the intervention group, or in the wait-list control group). An onsite care provider will be trained to tailor the video calls, and facilitate positive verbal and non-verbal engagement during the calls. The investigators will evaluate how Connecting Today affects outcomes for residents (quality of life, loneliness, and responsive behaviours) and their remote visitors (quality of life, loneliness, and social support). The investigators will assess how outcomes differ for men, women, and people with different perceptions and experiences of Connecting Today.",[68,69,70],"Dementia in Nursing Home","Family","Remote Visits",[72,73,74],"Quality of life","Loneliness","Social support","RECRUITING",{"date":45,"type":46},{"date":78,"type":46},"2026-06-09",{"date":80,"type":22},"2026-09-30",{"name":52,"class":53},{"id":83,"slug":84,"hasResults":12,"nctId":85,"briefTitle":86,"officialTitle":87,"acronym":4,"eligibilityCriteria":88,"healthyVolunteers":12,"sex":18,"minAge":89,"maxAge":4,"enrollmentInfo":90,"targetDuration":4,"studyType":23,"phases":92,"briefSummary":93,"conditions":94,"keywords":4,"overallStatus":75,"whyStopped":4,"lastUpdateSubmitDate":43,"lastUpdatePostDateStruct":96,"startDateStruct":97,"completionDateStruct":99,"leadSponsor":101,"locationsCount":54},"100514366","perioperative-prehabilitation-on-markers-of-fitness-and-frailty-in-patients-undergoing-elective-surgery-100514366","NCT05977556","Perioperative Prehabilitation on Markers of Fitness and Frailty in Patients Undergoing Elective Surgery","The Effect of Perioperative Prehabilitation on Markers of Fitness and Frailty in Patients Undergoing Elective Surgery: a Pilot, Pragmatic, Randomized Controlled Trial","Inclusion Criteria:\n\n* 50 years of age or older\n* score of 4-6 (vulnerable, mildly or moderately frail) on the clinical frailty scale (CFS)\n* scheduled for elective surgery\n* ambulatory (indoor and\u002For outdoor) with or without gait aids\n\nExclusion Criteria:\n\n* Unstable medical conditions that limit exercise tolerance such as ME\u002FCFS","50 Years",{"count":91,"type":22},50,[25],"A growing body of evidence suggests that patients who receive good perioperative care (i.e. care prior to surgery, during surgery, and after surgery) tend to have fewer complications, quicker recovery times, and shorter hospital stays. A key component of good perioperative care is recognizing individuals who have diminished physiological reserves (i.e. those who are vulnerable or frail). The stress of an invasive procedure can exhaust the diminished reserves of patients who are frail, which can in turn lead to perioperative complications, mortality and an increase burden to the healthcare system.\n\nEarly interventions in patients with diminished reserves can be applied to reduce the risk of complications and poor outcomes. There are emerging studies that show promising benefits of perioperative interventions, such as prehabilitation, though with some mixed findings. Exercise has been shown to reverse or modify the molecular driving factors of frailty, which involve dysregulation of cytokine and endocrine pathways.\n\nPhysical inactivity and prolonged sedentary behaviors are also emerging concerns in frailty because of the implicated deleterious health effects. Sedentary behaviors are associated with prevalence and severity of frailty. Among pre-frail and frail inactive adults, sedentary time is associated with higher mortality. Increasing physical activity is recommended as the most feasible approach to prevent and treat frailty. The aim of this study is to determine if a prehabilitation intervention that combines neuromuscular strength training and intervention to reduce sedentary behavior reduces complications, length of stay, and patient recovery, thereby also reducing the burden on the healthcare system.",[95],"Frailty",{"date":45,"type":46},{"date":98,"type":22},"2026-07",{"date":100,"type":22},"2028-06",{"name":52,"class":53},{"id":103,"slug":104,"hasResults":12,"nctId":105,"briefTitle":106,"officialTitle":107,"acronym":108,"eligibilityCriteria":109,"healthyVolunteers":12,"sex":18,"minAge":110,"maxAge":111,"enrollmentInfo":112,"targetDuration":4,"studyType":23,"phases":114,"briefSummary":117,"conditions":118,"keywords":4,"overallStatus":42,"whyStopped":4,"lastUpdateSubmitDate":122,"lastUpdatePostDateStruct":123,"startDateStruct":125,"completionDateStruct":126,"leadSponsor":128,"locationsCount":4},"100645261","phase-1-taurine-supplementation-in-adolescents-with-post-covid-condition-100645261","NCT07682402","Taurine Supplementation in Adolescents With Post-COVID Condition","An Open-Label Study of Taurine Supplementation in Adolescents With Post-COVID Condition: Quantifying Taurine Plasma Levels and Evaluating Clinical and Biological Outcomes","TaurineLCPeds","Inclusion Criteria:\n\n1. Subjects must be between 10 and 17 years of age at the time of study enrollment\n2. Positive COVID-19 test by nasopharyngeal swab RT-PCR test, antibody or antigen tests at least 3 months prior to trial; OR Presumed COVID-19 assessed by the site investigator (no positive COVID-19 test) with acute illness after October 15, 2019, and at least 3 months prior to trial enrollment.\n3. If participants have treatable symptoms, they should have had a stable regimen of treatment prior to entering the study (i.e. started treatment for at least 4 weeks).\n4. Lingering COVID-19 symptoms beyond 3 months from onset of acute COVID and symptoms have lasted at least 2 months. The onset of COVID is considered the earliest of two dates: the date of positive testing or the date of first symptoms.\n5. Lingering symptoms from COVID-19 present at the time of trial enrollment.\n6. Individuals of childbearing potential (as assessed by the overseeing Investigator) who are sexually active must agree to practice true abstinence or use at least one highly effective method of contraception while on study treatment. Highly effective methods of contraception must be discussed and approved by the overseeing Investigator.\n7. Medication(s) only available through a prescription for the purposes of treating fatigue or cognitive function have been discontinued for four weeks prior to randomization.\n8. Participants must be able to assent to their participation in the study and be both willing and able to comply with study requirements.\n9. Parents\u002Fcaregivers\u002Fguardians must be able to provide informed consent for participation.\n10. Participants must agree to avoid taking supplemental taurine (e.g. from over-the-counter preparations, energy drinks, etc.)\n\nExclusion Criteria:\n\n1. Patients who had mechanical ventilation or extracorporeal membrane oxygen (ECMO) for COVID-19.\n2. Current end-organ failure, organ transplantation, or current hospitalization in an acute care hospital.\n3. Contraindications to the study intervention.\n4. Currently already on the study intervention (Participants would be eligible if they stopped taking Taurine for a minimum of 4 weeks prior to enrollment).\n5. Co-enrolment in another interventional trial (co-enrolment in an observational study is permitted).\n6. Currently pregnant or breastfeeding.\n7. The participant is currently enrolled in another research trial to treat neurocognitive symptoms in LC.","10 Years","17 Years",{"count":113,"type":22},30,[115,116],"PHASE1","PHASE2","The COVID-19 pandemic has swept across the globe, affecting millions of individuals with varying degrees of severity. While many individuals recover from the acute phase of the infection, a significant proportion continue to experience persistent and debilitating symptoms long after the initial SARS-CoV-2 infection. This condition, known as Long COVID (LC) or sometimes referred to as Post-COVID Condition (PCC) or post-acute sequelae of COVID-19 (PASC), has emerged as a complex multisystemic condition and challenging public health issue.\n\nContrary to initial perceptions, pediatric Long COVID is a significant health concern, with studies suggesting its prevalence ranges from 10% to 25% following infection. Research in the pediatric population has largely been limited to observational studies based on self-reported symptoms or large electronic healthcare datasets. The long-term outcomes and predictors of LC in children remain poorly described, highlighting an urgent need for further mechanistic research to characterize this complex condition. While acute COVID-19 symptoms are often milder in children relative to adults, some go on to develop a range of chronic physical, immunological, psychological, and neurological symptoms persisting for weeks to years after initial infection. The most commonly reported symptoms are similar to those seen in adults and include debilitating fatigue, respiratory distress, headaches, gastrointestinal symptoms, and neurocognitive impairment. Other frequently reported symptoms include muscle pain, sleep disturbances, olfactory and gustatory disturbances, exercise intolerance, and heart palpitations\u002Fcardiovascular symptoms. These symptoms can be new, or they may persist or fluctuate from the initial illness. Additionally, many children with LC experience psychological symptoms such as anxiety, depression, and mood disturbances, which are thought to be exacerbated by experiencing prolonged illness and subsequent lifestyle disruptions.\n\nCurrently, effective treatments for LC remain elusive, leaving patients to contend with persistent symptoms that significantly impair their quality of life. For children and adolescents, these issues can profoundly impact their daily activities, academic performance, and social interactions\u002Ffriendships. Symptoms like debilitating fatigue, cognitive impairment, and mood disturbances are especially disruptive by interfering with memory, energy levels, and overall development, often leading to school absenteeism, social withdrawal, and psychological distress. Therefore, it is imperative to explore novel therapeutic approaches that may alleviate the suffering of this patient population.",[119,120,121],"Long COVID","Post COVID-19 Condition","PASC Post Acute Sequelae of COVID 19","2026-06-26",{"date":124,"type":46},"2026-07-02",{"date":80,"type":22},{"date":127,"type":22},"2028-12-31",{"name":52,"class":53},{"id":130,"slug":131,"hasResults":12,"nctId":132,"briefTitle":133,"officialTitle":133,"acronym":134,"eligibilityCriteria":135,"healthyVolunteers":17,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":136,"targetDuration":4,"studyType":23,"phases":138,"briefSummary":139,"conditions":140,"keywords":4,"overallStatus":42,"whyStopped":4,"lastUpdateSubmitDate":122,"lastUpdatePostDateStruct":142,"startDateStruct":144,"completionDateStruct":145,"leadSponsor":147,"locationsCount":4},"100625861","heart-failure-efficacy-and-research-trial-heart-platform-100625861","NCT07428135","Heart Failure Efficacy and Research Trial (HEART) Platform","HEART","Inclusion Criteria (HEART Platform)\n\n* Participants are eligible for inclusion if they meet all of the following:\n* Age ≥18 years (or legal age of majority in participant's country of residence).\n* Diagnosis of heart failure, and eligible to be classified into one of the HEART platform states at the time of randomization:\n* State 1: Worsening Heart Failure (WHF): currently hospitalized for acute decompensated heart failure or emergency department patients requiring intravenous therapy for heart failure; OR\n* State 2: Ambulatory Heart Failure: stable outpatients with established heart failure diagnosis, receiving ongoing HF management and without HF hospitalization within the prior 30 days.\n* Able and willing to provide written informed consent (or consent via a legally authorized representative, where applicable).\n* Meets all applicable domain-specific eligibility criteria for at least one active HEART Platform domain at the time of screening\u002Frandomization.\n\nExclusion Criteria (HEART Platform)\n\n* Participants will be excluded if any of the following apply:\n* Inability to provide informed consent (and no legally authorized representative available when applicable).\n* Not eligible for assignment to either HEART platform state (State 1 or State 2).\n* Presence of conditions or circumstances that, in the investigator's opinion, would make study participation unsafe or not feasible (e.g., inability to comply with study procedures or follow-up).\n* Does not meet the eligibility requirements for any active HEART Platform domain.\n* Any domain-specific exclusion criteria applicable to the intervention\u002Fdomain(s) for which the participant would otherwise be eligible.\n* Additional inclusion and exclusion criteria apply for each individual HEART Platform domain and will be specified in the relevant domain protocol(s).",{"count":137,"type":22},1000,[25],"The Heart Failure Efficacy and Research Trial (HEART) Platform is a multicenter, randomized platform study designed to improve outcomes for patients with heart failure through the simultaneous and sequential evaluation of multiple interventions across the spectrum of heart failure.",[141],"Heart Failure",{"date":143,"type":46},"2026-06-30",{"date":98,"type":22},{"date":146,"type":22},"2037-03",{"name":52,"class":53},{"id":149,"slug":150,"hasResults":12,"nctId":151,"briefTitle":152,"officialTitle":153,"acronym":4,"eligibilityCriteria":154,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":155,"targetDuration":4,"studyType":23,"phases":157,"briefSummary":158,"conditions":159,"keywords":161,"overallStatus":42,"whyStopped":4,"lastUpdateSubmitDate":164,"lastUpdatePostDateStruct":165,"startDateStruct":166,"completionDateStruct":167,"leadSponsor":169,"locationsCount":54},"100645388","perioperative-rehab-for-inguinal-hernia-repair-100645388","NCT07680777","Perioperative Rehab for Inguinal Hernia Repair","Perioperative Rehabilitation for Individuals Undergoing Inguinal Hernia Repair: A Randomized Controlled Trial","Inclusion Criteria:\n\n* scheduled to undergo first time elective inguinal hernia repair\n* willing to participate in a 6-week exercise program before and after surgery\n* internet access: ability to communicate via email and Zoom\n* at least 18 years of age\n* no medical contraindications to exercise\n\nExclusion Criteria:\n\n* recurrent hernia\n* poorly controlled comorbidities that may prevent safe participation in exercise\n* use of opiates and\u002For opioids",{"count":156,"type":22},98,[25],"Despite how common inguinal hernia repair (IHR) surgery is, there is little research on how best to prepare people for this operation. Surgeons' advice to patients about exercise and physical activity are inconsistent and usually based on their clinical opinion. Some surgeons recommend exercise to help prepare for the operation while others say to rest. Research is needed to help know whether exercise is helpful before and after IHR surgery.\n\nThis study will observe the effects of education and exercise before and immediately after IHR surgery. Half of the participants will be randomized to an education and exercise group and the other half to a non-exercise, care as usual group. Participant outcomes will be measured up to 3 months after their surgery. It is expected that participants in the education and exercise group will have: 1) less pain at follow-up, 2) better hernia-related outcomes, 3) quicker return to activity and work, and 4) improved overall experience surrounding IHR surgery. This project will help in developing clear guidelines for pre- and post-operation to better prepare patients for IHR surgery.",[160],"Inguinal Hernia",[162,163],"rehabilitation","prehabilitation","2026-06-25",{"date":124,"type":46},{"date":48,"type":22},{"date":168,"type":22},"2027-12",{"name":52,"class":53},{"id":171,"slug":172,"hasResults":12,"nctId":173,"briefTitle":174,"officialTitle":174,"acronym":4,"eligibilityCriteria":175,"healthyVolunteers":17,"sex":18,"minAge":176,"maxAge":176,"enrollmentInfo":177,"targetDuration":4,"studyType":23,"phases":179,"briefSummary":180,"conditions":181,"keywords":186,"overallStatus":42,"whyStopped":4,"lastUpdateSubmitDate":164,"lastUpdatePostDateStruct":200,"startDateStruct":201,"completionDateStruct":202,"leadSponsor":204,"locationsCount":54},"100644993","breaking-the-cycle-real-time-family-oral-microbial-transmission-patterns-as-intervention-targets-100644993","NCT07674888","Breaking the Cycle: Real-Time Family Oral Microbial Transmission Patterns as Intervention Targets","Inclusion Criteria:\n\n* Families with at least two children aged 5-12 years living in the same household.\n* least one parent or guardian diagnosed with Stage II or III periodontitis requiring non-surgical periodontal therapy.\n* At least one child who has undergone caries treatment and is considered at high risk for disease recurrence.\n* Willingness of all participating household members to provide oral samples and participate in study procedures.\n* Ability of participants or their legal guardians to provide informed consent, and assent from children where applicable.\n\nExclusion Criteria:\n\n* Children living in multiple households or shared-custody arrangements during the study period.\n* Households unable to complete study visits or follow-up procedures.\n* Individuals unwilling or unable to comply with study procedures.\n* Individuals who do not provide informed consent or assent, where applicable.\n* Medical or behavioral conditions that, in the opinion of the investigators, would preclude safe participation in the study.","5 Years",{"count":178,"type":22},225,[25],"This study aims to understand how oral bacteria that cause tooth decay and gum disease spread among family members and whether treating multiple family members can reduce the return of these bacteria after dental treatment.\n\nFamilies with children aged 5-12 years will be recruited from university dental clinics. Participants will be assigned to one of three treatment groups: treatment for the child only, treatment for the child and parents, or treatment for all family members. Researchers will collect oral bacterial samples from family members before and after treatment and will monitor close-contact interactions within the household using wearable proximity-tracking devices.\n\nThe study will also collect information about oral health habits, family interactions, and environmental factors that may influence bacterial transmission. By combining bacterial DNA analysis with information about family contact patterns, researchers hope to better understand how oral bacteria are shared within households and whether family-based treatment approaches can reduce bacterial recolonization after dental therapy.\n\nThe results of this study may help improve strategies for preventing childhood tooth decay and gum disease by addressing family-level sources of bacterial transmission.",[182,183,184,185],"Dental Caries","Periodontitis","Oral Microbiome","Bacterial Transmission",[187,188,189,190,191,192,193,194,195,196,197,198,199],"family microbial transmission","Oral microbiome","Plaque recolonization","Pediatric oral health","Real-time proximity tracking","Ultrawide Band (UWB)","Oral bacterial transmission","Intergenerational pathogen transfer","Biofilm disruption","Periodontal disease","Family-based intervention","Microbial source tracking","Oral Health",{"date":143,"type":46},{"date":80,"type":22},{"date":203,"type":22},"2028-06-30",{"name":52,"class":53},{"id":206,"slug":207,"hasResults":12,"nctId":208,"briefTitle":209,"officialTitle":210,"acronym":4,"eligibilityCriteria":211,"healthyVolunteers":17,"sex":18,"minAge":212,"maxAge":213,"enrollmentInfo":214,"targetDuration":4,"studyType":23,"phases":216,"briefSummary":217,"conditions":218,"keywords":223,"overallStatus":75,"whyStopped":4,"lastUpdateSubmitDate":164,"lastUpdatePostDateStruct":228,"startDateStruct":229,"completionDateStruct":231,"leadSponsor":233,"locationsCount":54},"100495628","comparison-of-mi-paste-plus-and-resin-infiltration-in-white-spot-lesions-following-orthodontic-treatment-100495628","NCT05733676","Comparison of MI Paste Plus and Resin Infiltration in White Spot Lesions Following Orthodontic Treatment","Comparison of MI Paste Plus and Resin Infiltration in Improvement of White Spot Lesions Following Fixed Orthodontic Treatment: A Randomized Controlled Trial","Inclusion Criteria:\n\n* Individuals in the age range of 12-21 years who had undergone fixed orthodontic appliance therapy for a duration of 12-36 months.\n* Should have at least one white spot lesion on the labial surface of either maxillary or mandibular anterior teeth after debonding. Lesion visible with or without drying the lesion surface.\n* Patients with mild to moderate plaque accumulation. Fair oral hygiene. With a simplified Oral Hygiene Index of no more than 1.3-3.0\n\nExclusion Criteria:\n\n* Poor oral hygiene Simplified Oral Hygiene Index of 3.1-6.0 or more\n* Patients with hypoplasia or any developmental defects on the buccal of upper or lower incisors\n* Patients with any restorations on the buccal of upper or lower incisors\n* Patients that have presented WSL on the buccal of upper or lower incisors before orthodontic treatment was initiated.\n* Patients that have received any re-mineralizing agent other than regular toothpaste during the last three months\n* Patient with allergy to milk or any of their products\n* Patient with any medical \u002F oral or mental condition\n* Patients or legal guardians that does not speak or read English","12 Years","21 Years",{"count":215,"type":22},62,[25],"Dental cavities are among the most frequent diseases that affect teeth, particularly in patients who are treated with braces due to the difficulty in maintaining good oral hygiene in the presence of the mouth appliances. The white spot lesion (WSL) is the first clinical sign of cavities that presents itself as a milky-white opacity when located on the front face of the tooth. The aim to manage these early lesions focuses on promoting natural remineralization and preventing further demineralization. Various materials have been introduced for management of WSLs including MI paste and MI paste combined with fluoride (MI paste plus). Recently, a new material called resin infiltration has been found to treat these lesions with high esthetic results and great performance. According to the few numbers of in-vivo studies investigating the effectiveness of remineralization products, the aim of the current study is to clinically compare the outcome of the resin-infiltration and etching + MI paste plus to stop and improve the appearance of the WSL on front teeth in patients after treatment with braces.",[219,220,221,222],"White Spot Lesions","Orthodontic Appliance Complication","Caries Arrested","Smooth Surface Caries",[224,225,226,227],"White spot lesion","caries","arrested","orthodontic",{"date":143,"type":46},{"date":230,"type":46},"2023-05-30",{"date":232,"type":22},"2028-10-01",{"name":52,"class":53},{"id":235,"slug":236,"hasResults":12,"nctId":237,"briefTitle":238,"officialTitle":239,"acronym":4,"eligibilityCriteria":240,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":241,"targetDuration":4,"studyType":23,"phases":242,"briefSummary":243,"conditions":244,"keywords":246,"overallStatus":75,"whyStopped":4,"lastUpdateSubmitDate":251,"lastUpdatePostDateStruct":252,"startDateStruct":253,"completionDateStruct":255,"leadSponsor":257,"locationsCount":54},"100635533","high-intensity-walking-rehabilitation-in-outpatient-subacute-spinal-cord-injury-100635533","NCT07553923","High-intensity Walking Rehabilitation in Outpatient Subacute Spinal Cord Injury","High-intensity Walking Rehabilitation in Outpatient Subacute Spinal Cord Injury Rehabilitation: An Effectiveness-implementation Hybrid Study","Inclusion Criteria:\n\n* Adult (≥ 18 years of age)\n* Sustained a SCI within the past year\n* Motor incomplete SCI - classified as American Spinal Injury Association (ASIA) Impairment Scale levels C or D\n* Able to stand and initiate reciprocal steps through voluntary lower extremity movement but may require maximal physical assistance of at least one person and may include assistive devices (SWAT level 2A or above)\n* Indicate a walking-related goal on admission to outpatient physical therapy\n\nExclusion Criteria:\n\n* Medical or movement restriction(s) that limit high-intensity standing or walking rehabilitation (e.g., weight bearing restriction to lower extremities, cardiovascular constraints)\n* Inability to understand or communicate verbally in English",{"count":7,"type":22},[25],"People with incomplete spinal cord injury (SCI) often have some preserved movement and may regain walking ability, but recovery can be limited, and more effective rehabilitation approaches are needed.The goal of this clinical trial is to learn if high-intensity walking rehabilitation can improve walking recovery and overall neurological recovery in individuals with subacute SCI. The investigators are also exploring the process of incorporating this type of physical therapy approach in an outpatient rehabilitation setting.\n\nThe main questions it aims to answer are:\n\n* Does high-intensity walking rehabilitation improve walking ability, compared to usual care for individuals with subacute spinal cord injury?\n* What are some of the barriers and facilitators to delivering high-intensity walking rehabilitation in an outpatient setting?\n\nThe investigators will compare usual care rehabilitation to a high-intensity rehabilitation program to see if higher-intensity physical therapy leads to better walking outcomes and improved recovery. The study will also explore how feasible it is to deliver this type of program in a real-world outpatient rehabilitation setting and gather perspectives from both participants and clinicians.\n\nParticipants will:\n\n* Attend regular outpatient physical therapy sessions focused on walking rehabilitation\n* Receive either usual care or a higher-intensity walking program delivered by their physical therapist\n* Have their activities, heart rate, step counts, and self-reported effort during therapy sessions monitored\n* Complete walking, balance, and neurophysiological assessments at the start and end of rehabilitation\n* Wear an activity monitor for one week at the beginning and end of the study to measure daily activity outside of therapy\n* Participants who receive the higher-intensity intervention may participate in an interview to share their experiences with rehabilitation",[245],"Spinal Cord Injuries (SCI)",[247,248,249,250],"high-intensity","subacute","walking","physical therapy","2026-06-24",{"date":43,"type":46},{"date":254,"type":46},"2026-05-26",{"date":256,"type":22},"2027-10",{"name":52,"class":53},{"id":259,"slug":260,"hasResults":12,"nctId":261,"briefTitle":262,"officialTitle":263,"acronym":4,"eligibilityCriteria":264,"healthyVolunteers":12,"sex":18,"minAge":4,"maxAge":265,"enrollmentInfo":266,"targetDuration":268,"studyType":269,"phases":4,"briefSummary":270,"conditions":271,"keywords":276,"overallStatus":42,"whyStopped":4,"lastUpdateSubmitDate":251,"lastUpdatePostDateStruct":289,"startDateStruct":290,"completionDateStruct":292,"leadSponsor":294,"locationsCount":54},"100601384","national-surveillance-and-prevention-of-neonatal-vap-100601384","NCT07109791","National Surveillance and Prevention of Neonatal VAP","Developing a National Approach to Surveillance and Prevention for Neonatal Ventilator-Associated Pneumonia","INCLUSION CRITERIA:\n\n* All VLBW infants admitted to participating tertiary NICUs in Canada\n* All neonatal VAP events diagnosed based on the physicians' discretion\n\nEXCLUSION CRITERIA:\n\n* Infants with major congenital anomalies\n* Infants with moribund status on admission","24 Weeks",{"count":267,"type":22},1500,"6 Months","OBSERVATIONAL","The goal of this observational study is to improve how hospital-acquired lung infections (called ventilator-associated pneumonia, or VAP) are diagnosed, treated and prevented in very low birth weight (VLBW) infants, babies born very early (preterm) or very small who often require respiratory support in hospital's neonatal intensive care units (NICUs).\n\nThe main questions it aims to answer are:\n\n* How often do very-low-birth-weight (VLBW) infants get ventilator-associated pneumonia (VAP) in hospitals across Canada?\n* How often are these VAP infections caused by germs that are resistant to antimicrobials (also known as antimicrobial-resistant organisms or AROs)?\n* What types of antimicrobial-resistant germs (AROs) are causing them?\n* How are these infections being treated with antibiotics, and can we reduce unnecessary antibiotic use?\n* Which diagnostic definition is the best and most accurate for diagnosing VAP in newborns, based on real patient data and expert agreement?\n* Can we use this information to create clear, evidence-based guidelines that help hospitals prevent and treat VAP in the same, effective way?\n\nResearchers will compare how different hospitals define, report, and manage VAP to devise a shared, evidence-based approach that will lead to more accurate diagnoses and better treatment and outcomes for neonatal VAP.\n\nResearchers will:\n\n* Use data already collected in hospital records (per existing standard of clinical care).\n* Analyse how often VAP occurs, how it is diagnosed, and how it is treated\n* Work with experts and hospitals to develop and implement a standard, evidence-based plan for diagnosing, managing and preventing VAP in newborns\n\nThe overarching goal is to create a clear, nationwide approach to ensure hospitals across Canada care for preterm babies in a standardized manner, reduce infection rates, avoid unnecessary antibiotic use, and improve outcomes for these vulnerable infants.",[272,273,274,275],"Ventilator-Associated Pneumonia (VAP), Neonatal","Bronchopulmonary Dysplasia (BPD)","Antibiotic-Resistant Organisms (AROs)","Health-Care Associated Infection (HAI)",[277,278,279,280,281,282,283,284,285,286,287,288],"Preterm","Neonate","Neonatal intensive care unit (NICU)","Ventilator-Associated Pneumonia (VAP)","Healthcare-associated infections (HAI)","Invasive mechanical ventilation (IMV)","Bronchopulmonary dysplasia (BPD)","Antibiotic-resistant organisms (AROs)","Antimicrobial stewardship","Implementation science","Quality improvement (QI)","Infection surveillance",{"date":164,"type":46},{"date":291,"type":22},"2026-10-01",{"date":293,"type":22},"2029-09",{"name":52,"class":53},{"id":296,"slug":297,"hasResults":12,"nctId":298,"briefTitle":299,"officialTitle":300,"acronym":301,"eligibilityCriteria":302,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":303,"enrollmentInfo":304,"targetDuration":4,"studyType":23,"phases":305,"briefSummary":306,"conditions":307,"keywords":310,"overallStatus":42,"whyStopped":4,"lastUpdateSubmitDate":251,"lastUpdatePostDateStruct":314,"startDateStruct":315,"completionDateStruct":317,"leadSponsor":318,"locationsCount":4},"100549392","pause-sick-day-medication-management-mobile-app-study-100549392","NCT06433414","PAUSE: Sick Day Medication Management Mobile App Study","Preventing Medication Complications During AcUte Illness Through Symptom Evaluation and Sick Day Guidance Mobile Application (PAUSE)","PAUSE","Inclusion Criteria:\n\n* ≥18 years of age and able to provide informed consent\n* be able to communicate (read, write, and speak) in English\n* have access to a smartphone\u002Ftablet with an Internet connection\n* be willing and able to download and use the PC Health app for the duration of the study\n* currently be taking 2 or more medications from the following classes: renin-angiotensin-aldosterone system (RAAS) antagonists, diuretics, oral NSAIDs, metformin, or 1 or more medications from the following classes: insulin, sulfonylureas, meglitinides, SGLT2 inhibitors.\n\nExclusion Criteria:\n\n* fail to meet the inclusion criteria\n* have kidney failure requiring maintenance dialysis\n* have had an organ transplant\n* are pregnant\n* receive qualifying medications in a blister pack or sachet\n* do not primarily manage their own medications and condition (i.e., receive home care, in a rehabilitation or medical respite facility)\n* cannot use the PC Health app independently\n* previously participated in studies that led to the development of the PAUSE App (including the PAUSE study usability testing or needs assessment focus groups)","99 Years",{"count":64,"type":22},[25],"Diabetes, heart disease and kidney disease have high morbidity and costs of care. Medications used to treat these conditions are effective. Yet, some have the risk of preventable adverse events when people are sick with the flu or stomach bug. These events include low blood sugar and acute kidney injury which can lead to extended hospital stays or death. Sick day medication guidance (SDMG) recommends stopping these medications temporarily when sick and restarted after symptoms subside. Unfortunately, many patients are not aware of these recommendations or find them hard to follow.\n\nThe investigator's previous research has shown that there is a lack of SDMG education and patient resources. Research on the development, implementation, usability and efficacy of these resources is also limited. In developing a SDMG tool, the investigators surveyed patients who expressed interest in an electronic health (eHealth) tool. As a result, the PAUSE App provides a timely and innovative way to provide continuity of care to patients that is linked to each patients' unique pharmacy record.\n\nIn the present pilot randomized control trial, the investigators will examine the outcomes of the PAUSE Initiative consisting of the PAUSE App and a SDMG educational handout. Approximately 16 Loblaw\u002FShoppers Drug Mart pharmacies across Alberta will take part. Patients of these pharmacies who take high-risk medications will be invited to participate. Each pharmacy will be randomized to provide their patients usual care (i.e. SDMG handout) or the intervention (i.e., PAUSE App + handout). Approximately 320 participants (20 per pharmacy) are expected to be recruited. The expected trial length is 9 months from recruitment to analysis.\n\nA simulated 'sick day' survey will be used to assess the fidelity and efficacy of the PAUSE Initiative. Feasibility of the study processes (i.e., recruitment, onboarding) will be assessed to inform a full-scale trial. The usability and acceptability of the PAUSE App will also be investigated. Pharmacists and participants will complete questionnaires and qualitative interviews to assess these outcomes. Additionally, PAUSE App user metrics will be collected. All participants will receive an honorarium for their time.",[308,309],"Chronic Condition","Adverse Event",[311,312,313],"chronic condition","medication safety","sick day medication guidance",{"date":164,"type":46},{"date":316,"type":22},"2027-01-01",{"date":168,"type":22},{"name":52,"class":53},{"id":320,"slug":321,"hasResults":12,"nctId":322,"briefTitle":323,"officialTitle":323,"acronym":4,"eligibilityCriteria":324,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":325,"targetDuration":4,"studyType":23,"phases":327,"briefSummary":328,"conditions":329,"keywords":335,"overallStatus":75,"whyStopped":4,"lastUpdateSubmitDate":338,"lastUpdatePostDateStruct":339,"startDateStruct":340,"completionDateStruct":342,"leadSponsor":344,"locationsCount":54},"100633265","improving-the-care-of-incontinence-associated-dermatitis-iad-using-a-beta-glucan-cream-as-a-hydrating-and-soothing-agent-100633265","NCT07524439","Improving the Care of Incontinence-Associated Dermatitis (IAD) Using a Beta-Glucan Cream as a Hydrating and Soothing Agent","Eligible participants are adults (≥18 years) with IAD secondary to urinary and\u002For fecal incontinence and an expected hospital stay of ≥7 days. Written informed consent will be obtained directly or via substitute decision-maker. Exclusion criteria include absence of IAD or incontinence, pediatric patients, and participants with known hypersensitivities to components of cream (e.g. beta-glucan).",{"count":326,"type":22},60,[25],"The goal of this clinical trial is to determine whether adding a β-glucan moisturizing cream to routine skin care can enhance skin healing, accelerate visible recovery, reduce discomfort, and improve both patient and clinician experiences. The study will also learn about the safety and tolerability of the β-glucan cream when used along with standard skin care.\n\nThe main questions it aims to answer are:\n\nAre there visible changes in the severity of IAD when β-glucan cream is added to standard care, and if so, to what extent does it reduce severity compared with standard care alone?\n\nDoes the β-glucan cream help IAD heal faster?\n\nDoes the cream reduce symptoms such as pain, itching, tingling, or burning?\n\nWhat medical problems or side effects, if any, do participants experience while using the β-glucan cream?\n\nResearchers will compare standard care plus β-glucan cream to standard care alone to see if the β-glucan cream provides additional benefit for treating IAD.\n\nParticipants will:\n\nReceive either β-glucan cream plus standard care or standard care alone\n\nHave the study cream applied once daily for up to 2 weeks\n\nHave their skin checked weekly by the study team using a standardized assessment tool\n\nAnswer questions about symptoms such as pain, itching, tingling, and burning\n\nAllow photographs of the affected skin area to be taken for secure clinical review\n\nBe monitored for any side effects or skin reactions during the study",[330,331,332,333,334],"Fecal Incontinence","Urinary Incontinence","Diaper Rash","Irritant Contact Dermatitis Caused by Faeces","Irritant Contact Dermatitis",[336,337],"Administration, Topical","Administration, Cutaneous","2026-06-23",{"date":122,"type":46},{"date":341,"type":46},"2026-05-01",{"date":343,"type":22},"2028-11-30",{"name":52,"class":53},{"id":346,"slug":347,"hasResults":12,"nctId":348,"briefTitle":349,"officialTitle":349,"acronym":350,"eligibilityCriteria":351,"healthyVolunteers":12,"sex":18,"minAge":89,"maxAge":4,"enrollmentInfo":352,"targetDuration":4,"studyType":23,"phases":354,"briefSummary":355,"conditions":356,"keywords":4,"overallStatus":75,"whyStopped":4,"lastUpdateSubmitDate":338,"lastUpdatePostDateStruct":360,"startDateStruct":361,"completionDateStruct":363,"leadSponsor":364,"locationsCount":54},"100568432","pharmacist-physiotherapist-collaborative-management-for-early-knee-osteoarthritis-100568432","NCT06681142","Pharmacist-physiotherapist Collaborative Management for Early Knee Osteoarthritis","PACE-OA","Inclusion Criteria:\n\n* regularly experiencing pain, aching, or stiffness in and\u002For around the knee for at least 1 month\n* complete the screening PhIT-OA questionnaire\n\nExclusion Criteria:\n\n* Prior total knee replacement or on the waitlist to have your knee replaced\n* Knee surgery within the previous 4 months\n* History of acute injury to knee within previous 6 months\n* Unable to speak and read English\n* Unwilling or unable to visit a physiotherapist at a community physiotherapy clinic (specifically the dates and times of the partnering physiotherapy clinic)\n* Previous physician-diagnosed inflammatory arthritis (including this list): Rheumatoid arthritis, Psoriatic arthritis, Ankylosing spondylitis, Lupus, Gout\n* Physician diagnosed fibromyalgia\n* A sudden, severely painful, hot, swollen joint at any time in the past\n* History of the following medications: csDMARD or bDMARD or tsDMARD, Immunosuppressive, Allopurinol or febuxostat, Colchicine\n* Received a knee joint injection in the past 3 months or have one scheduled in the next 3 months\n* Has completed the GLA:D Hip and Knee program at all in the past",{"count":353,"type":22},125,[25],"Osteoarthritis (OA) is a slowly progressive chronic condition that is associated with aging and is characterized as joint pain. Individuals with early-stage OA usually do not seek medical attention. If and when they do, patients more often present to a pharmacy for over-the-counter medications.\n\nThe investigators want to leverage community pharmacists' accessibility and scope of practice to best support patients with early knee OA. Given there are no disease-modifying treatments for OA, treatment guidelines center on patient education, self-management, and exercise, with medications playing a supporting role. Self-management is an effective strategy that provides a solid foundation for managing this progressive chronic condition and health care professionals like physiotherapists and pharmacists can help with the development and application of these skills.",[357,358,359],"Osteoarthritis (OA) of the Knee","Physiotherapy","Pharmacy",{"date":122,"type":46},{"date":362,"type":46},"2025-08-13",{"date":50,"type":22},{"name":52,"class":53},{"id":366,"slug":367,"hasResults":12,"nctId":368,"briefTitle":369,"officialTitle":370,"acronym":371,"eligibilityCriteria":372,"healthyVolunteers":12,"sex":373,"minAge":19,"maxAge":4,"enrollmentInfo":374,"targetDuration":4,"studyType":23,"phases":376,"briefSummary":377,"conditions":378,"keywords":380,"overallStatus":75,"whyStopped":4,"lastUpdateSubmitDate":338,"lastUpdatePostDateStruct":383,"startDateStruct":384,"completionDateStruct":386,"leadSponsor":388,"locationsCount":389},"100482147","micro-ultrasound-in-cancer---active-surveillance-100482147","NCT05558241","Micro-UltraSound In Cancer - Active Surveillance","Micro-UltraSound In Cancer - Active Surveillance (MUSIC-AS)","MUSIC-AS","Inclusion Criteria:\n\n* Adult men with Gleason Grade Group 1 prostate cancer managed by active surveillance who require a confirmatory prostate biopsy\n\nExclusion Criteria:\n\n* Men who cannot undergo a prostate MRI\n* Men who cannot undergo a prostate biopsy","MALE",{"count":375,"type":22},210,[25],"This study will compare the two imaging modalities (MRI and micro-ultrasound) during Active Surveillance of prostate cancer (PCa). Progression to clinically significant PCa will be assessed by first taking micro-US targeted samples (while blinded to MRI results), followed by MRI targeted samples, finishing with 12 systematic biopsy cores. The primary goal is to compare microUS to MRI for the detection of ≥GG2 PCa at confirmatory biopsy. This study will also collect blood samples from participants to be used for future biomarker studies.",[379],"Prostate Cancer",[381,382],"Active surveillance","micro-ultrasound",{"date":164,"type":46},{"date":385,"type":46},"2022-11-30",{"date":387,"type":22},"2033-07-30",{"name":52,"class":53},6,{"id":391,"slug":392,"hasResults":12,"nctId":393,"briefTitle":394,"officialTitle":394,"acronym":4,"eligibilityCriteria":395,"healthyVolunteers":17,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":396,"targetDuration":4,"studyType":269,"phases":4,"briefSummary":398,"conditions":399,"keywords":401,"overallStatus":75,"whyStopped":4,"lastUpdateSubmitDate":338,"lastUpdatePostDateStruct":407,"startDateStruct":408,"completionDateStruct":410,"leadSponsor":412,"locationsCount":54},"100480660","body-structure-and-capacity-evaluation-of-adults-with-scoliosis-100480660","NCT05538871","Body Structure and Capacity Evaluation of Adults With Scoliosis","Inclusion criteria for the idiopathic scoliosis group :\n\n* Diagnosis of idiopathic scoliosis\n* Age ⩾18 years old\n* Curve severity over 10°\n* Fluent in English.\n\nInclusion criteria for the degenerative scoliosis group :\n\n* Diagnosis of degenerative (De novo) scoliosis\n* Age ⩾45 years old\n* Curve severity over 10°\n* Fluent in English.\n\nExclusion criteria for the scoliosis groups :\n\n* History of spine surgery or\n* History of diseases affecting the torso or lower extremity function\n* Surgery or trauma\n* Secondary scoliosis\n* Unable to fill out the questionnaires or attend the physical examination,\n* Pregnant or gave birth between 0 and 2 years ago.\n\nInclusion criteria for healthy groups:\n\n* Age ⩾ 18 years\n* Matched for age\u002Fheight\u002Fweight (+\u002F-5 years; +\u002F- 10 lbs; +\u002F- 10cm) to a scoliosis participant\n* Fluent in English\n\nExclusion criteria for healthy groups:\n\n* Serious systemic pathology\n* Spine deformity\n* Spine surgery\n* Pregnant or gave birth between 0 and 2 years ago\n* Unable to fill out the questionnaires or attend the physical examination\n* Received treatments for the spine\u002Fthe lower limbs within the last year",{"count":397,"type":22},108,"Adults with scoliosis have not been the focus of much research in physical therapy despite their prevalence being very important. Adults with idiopathic scoliosis have a reported prevalence of about 2-11%. This includes adolescents with idiopathic scoliosis who have become adults but still have a scoliosis. They do not get much treatment as the adolescent treatment focuses on preventing worsening of the curvatures and the risk of progression is significantly reduced once a person reaches skeletal maturity. Still some patients experience self-image, function and pain issues which may be amenable to treatment using specific exercises as was recently shown. With ageing population a growing number of adults with de novo degenerative scoliosis is observed. This is a spinal misalignment due to spine degeneration. Adult degenerative scoliosis with pain is thought to affect about 24% of the ageing adults. This population has not been investigated very much.\n\nBefore planning conservative treatments for adults with scoliosis it would be important to describe what deficit these adults present that may be targeted by physical therapy. The objective of this study is to compare samples of patients with adults degenerative scoliosis, adult idiopathic scoliosis to matched healthy controls (for age, height and weight). Participants will complete questionnaires and a physical exam to identify which limitations they present that may be amenable to treatment with physical therapy. This information will assist planning trials to address the needs of these two neglected patient populations.",[400],"Scoliosis",[400,402,403,404,405,406],"Degenerative scoliosis","Idiopathic scoliosis","Adult scoliosis","ICF","Deficits",{"date":164,"type":46},{"date":409,"type":46},"2019-05-06",{"date":411,"type":22},"2027-06",{"name":52,"class":53},{"id":414,"slug":415,"hasResults":12,"nctId":416,"briefTitle":417,"officialTitle":417,"acronym":418,"eligibilityCriteria":419,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":420,"enrollmentInfo":421,"targetDuration":4,"studyType":23,"phases":423,"briefSummary":424,"conditions":425,"keywords":434,"overallStatus":75,"whyStopped":4,"lastUpdateSubmitDate":445,"lastUpdatePostDateStruct":446,"startDateStruct":447,"completionDateStruct":449,"leadSponsor":451,"locationsCount":452},"100407038","randomized-comparison-of-partial-wrist-fusion-with-or-without-triquetral-excision-parte-100407038","NCT04580225","Randomized Comparison of PARtial Wrist Fusion With or Without Triquetral Excision (PARTE)","PARTE","Inclusion Criteria:\n\n* Participant has a stage II or III scapholunate advanced collapse (SLAC) or scaphoid nonunion advanced collapse (SNAC) wrist and is a surgical candidate for the included surgical interventions\n\nExclusion Criteria:\n\n* Participant has been diagnosed with other forms of wrist arthritis other than SLAC or SNAC\n* Participant has significant arthritis of the ipsilateral hand\u002Ffinger joint(s), major joint trauma, previous major wrist surgery, infection or neuromuscular pathology affecting the function of the ipsilateral upper extremity or ability to make a fist\n* Participant has a physical or mental health condition preventing completion of consent or questionnaires\n* Participant does not speak\u002Fread\u002Funderstand English\n* Participant has no fixed address or means of contact\n* Participant is unwilling to complete necessary follow-ups\n* Surgeon concludes that eligible salvage techniques are not appropriate at the time of surgery (based on injury characteristics or concomitant wrist pathology)","75 Years",{"count":422,"type":22},170,[25],"This randomized clinical trial (RCT) aims to compare clinical and radiographic outcomes of different partial wrist fusion techniques in participants with post-traumatic wrist arthritis. Participants with stage II or III scapholunate advanced collapse (SLAC) or scaphoid nonunion advanced collapse (SNAC) who meet the eligibility criteria will be randomly assigned to one of two parallel groups: Group A (partial wrist arthrodesis without triquetral excision i.e. four-corner arthrodesis), or Group B (partial wrist arthrodesis with triquetral excision i.e. three-corner or capitolunate arthrodesis with triquetral excision). The results of this study will provide evidence to guide surgeons in determining the ideal wrist fusion technique in the management of patients with post-traumatic wrist arthritis requiring surgery.",[426,427,428,429,430,431,432,433],"Wrist Arthritis","Wrist Arthropathy","Scapholunate Advanced Collapse","Scaphoid Nonunion","Post-traumatic; Arthrosis","Arthritis","Musculoskeletal Diseases","Joint Diseases",[435,436,437,438,439,440,441,442,443,444],"Post-traumatic wrist arthritis","Partial wrist fusions","Scapholunate advanced collapse","SLAC wrist","Scaphoid nonunion advanced collapse","SNAC wrist","Four-corner fusion","Bicolumnar wrist fusion","Three-corner fusion","Capitolunate fusion","2026-06-19",{"date":251,"type":46},{"date":448,"type":46},"2021-01-07",{"date":450,"type":22},"2027-04",{"name":52,"class":53},5,{"id":454,"slug":455,"hasResults":12,"nctId":456,"briefTitle":457,"officialTitle":458,"acronym":459,"eligibilityCriteria":460,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":461,"targetDuration":4,"studyType":23,"phases":463,"briefSummary":464,"conditions":465,"keywords":4,"overallStatus":75,"whyStopped":4,"lastUpdateSubmitDate":467,"lastUpdatePostDateStruct":468,"startDateStruct":470,"completionDateStruct":472,"leadSponsor":473,"locationsCount":474},"100501237","uptake-using-personalized-risk-and-digital-tools-to-guide-transitions-following-acute-kidney-events-100501237","NCT05806645","UPTAKE: Using Personalized Risk and Digital Tools to Guide Transitions Following Acute Kidney Events","UPTAKE: Using Personalized Risk and Digital Tools to Guide Transitions Following Acute Kidney Events- A Pragmatic Randomized Controlled Trial in Connect Care","UPTAKE-1","Inclusion Criteria:\n\n(all of)\n\n* Age ≥ 18 years old\n* Hospitalized at site using AHS EHR\n* Acute Kidney Injury (Stage 1-3) identified in hospital per KDIGO guideline criteria\n\nExclusion Criteria:\n\n(any of)\n\n* Pre-hospitalization advanced CKD: eGFR\\\u003C30 mL\u002Fmin\u002F1.73m2\n* Pre-hospitalization dialysis\n* Very low risk (\\\u003C1% risk) of advanced CKD\n* Non-Alberta resident\n* Palliative goals of care\n* Enrolled in the UPTAKE VC Trial\n* Admitted under a nephrologist at time of discharge\n* Dialysis on at least 2 days in the last week prior to discharge\n* Receiving apheresis\n* Kidney transplant recipient\n* Kidney transplant donor\n* Diagnosis of Glomerulonephritis\n* Cirrhosis AND complication of cirrhosis in medical history or active problem list (ascites, varices, hepatic encephalopathy, hepatorenal syndrome)",{"count":462,"type":22},6046,[25],"Nearly one in ten people who are hospitalized in Canada develop a complication with sudden loss of kidney function, called acute kidney injury (AKI). AKI may lead to other severe health problems after discharge home, such as kidney failure requiring dialysis treatment, heart failure, heart attacks, stroke, and even premature death. Discharge from hospital to home can be a difficult transition where there are often gaps in identification, communication, care coordination, education, and planning of care for AKI. The study team will co-design and evaluate a tailored post-discharge care plan that is based on the risk of later kidney problems and uses currently available, yet untapped digital innovation to improve the health and experience of people with AKI.\n\nThis study will be built into Alberta's new Epic Systems based provincial electronic health record (EHR). The plan is to use digital tools in the EHR to identify all people in Alberta hospitals that have had an AKI event and are at increased risk of long-term complications. Half will randomly be assigned to receive a tailored care plan based on their risk at hospital discharge while the other half will receive care as it is currently provided by their healthcare team. The electronic health system will automatically calculate a patient's risk and report this risk in their chart along with recommendations for care. The study team includes patients, healthcare providers, and health system decision makers needed to co-develop the proposed strategy and introduce the changes needed to deliver this intervention. The investigators will study whether this strategy can reduce health problems that may happen after AKI including death, chronic kidney disease (CKD), kidney failure, heart attacks, and stroke. The investigators will also determine if the approach improves patient experience during the transition from hospital to home. This study has the potential to revolutionize how we care for people that leave hospital after having AKI.",[466],"Acute Kidney Injury","2026-06-08",{"date":469,"type":46},"2026-06-10",{"date":471,"type":46},"2025-02-12",{"date":293,"type":22},{"name":52,"class":53},2,{"id":476,"slug":477,"hasResults":12,"nctId":478,"briefTitle":479,"officialTitle":480,"acronym":4,"eligibilityCriteria":481,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":482,"targetDuration":4,"studyType":23,"phases":484,"briefSummary":485,"conditions":486,"keywords":488,"overallStatus":42,"whyStopped":4,"lastUpdateSubmitDate":492,"lastUpdatePostDateStruct":493,"startDateStruct":494,"completionDateStruct":496,"leadSponsor":498,"locationsCount":4},"100643685","timing-of-rehabilitation-following-cervical-spinal-surgery-in-degenerative-myelopathy-100643685","NCT07636135","Timing of Rehabilitation Following Cervical Spinal Surgery in Degenerative Myelopathy","Feasibility of Early Post-operative Rehabilitation Following Cervical Spinal Surgery in Degenerative Myelopathy","Inclusion Criteria:\n\n* adult (\\>18 years of age) with diagnosis of degenerative cervical myelopathy, within 2 weeks of spinal decompression surgery\n* plan to be discharged home from acute care (i.e., not admitted to another facility for post-operative rehabilitation)\n* able to stand with a maximum of one-person assist (+\u002F- use of gait aid)\n* persistent functional impairment in lower extremity strength, balance, coordination, and\u002For gait\n* ability to attend an 8-week in-person rehabilitation program in Edmonton, Alberta\n\nExclusion Criteria:\n\n* discharge from acute care facility \\> 2 weeks post-operative\n* intra-operative or early post-operative complication delaying discharge or precluding participation in early rehabilitation",{"count":483,"type":22},20,[25],"The goal of this clinical trial is to learn whether starting rehabilitation earlier after surgery can improve recovery and is feasible and acceptable for adults with degenerative cervical myelopathy (DCM) undergoing cervical spine surgery. The main question it aims to answer is:\n\nDoes starting rehabilitation earlier improve walking, balance, physical activity, quality of life, and nervous system function after surgery?\n\nResearchers will compare participants who begin rehabilitation two weeks after surgery with participants who begin rehabilitation six weeks after surgery to see if earlier rehabilitation leads to better recovery outcomes and participation.\n\nParticipants will:\n\nBe randomly assigned to begin rehabilitation either two weeks or six weeks after surgery.\n\nAttend physical therapy sessions twice per week for eight weeks focused on strength, balance, and walking.\n\nComplete assessments of walking ability, balance, physical activity, quality of life, and nervous system function over several months after surgery.\n\nProvide feedback about their experience with the rehabilitation program, including satisfaction and any side effects or challenges related to participation.",[487],"Cervical Myelopathy",[250,489,249,490,491],"post-operative rehabilitation","degenerative cervical myelopathy","spinal cord injury","2026-06-04",{"date":78,"type":46},{"date":495,"type":22},"2026-06-15",{"date":497,"type":22},"2027-12-31",{"name":52,"class":53},{"id":500,"slug":501,"hasResults":12,"nctId":502,"briefTitle":503,"officialTitle":504,"acronym":505,"eligibilityCriteria":506,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":507,"targetDuration":4,"studyType":23,"phases":508,"briefSummary":509,"conditions":510,"keywords":4,"overallStatus":42,"whyStopped":4,"lastUpdateSubmitDate":512,"lastUpdatePostDateStruct":513,"startDateStruct":514,"completionDateStruct":515,"leadSponsor":517,"locationsCount":54},"100626348","ketone-ester-for-treatment-of-acute-heart-failure-100626348","NCT07434466","Ketone Ester for Treatment Of Acute Heart Failure","KETO-AHF: Ketone Ester for Treatment Of Acute Heart Failure: A Vanguard Randomized Controlled Trial","KETO-AHF","Domain-Specific Inclusion Criteria:\n\n1. Primary diagnosis of AHF with dyspnea on exertion or at rest, and at least two of the following: congestion on chest radiograph, rales on chest auscultation, clinically relevant edema, or an elevated jugular venous pressure \\[21\\]\n2. Admitted to the hospital for less than 48 hours\n3. Estimated glomerular filtration rate above 15 mL\u002Fmin\u002F1.73m²\n4. NT-proBNP ≥ 1000 pg\u002Fml\n\nDomain-Specific Exclusion Criteria:\n\n1. Type 1 diabetes mellitus\n2. Patients on mechanical circulatory support\n3. Patients on more than one inotrope or on inopressors\n4. Patients on dialysis\n5. Patients with non-functioning enteral tracks",{"count":326,"type":22},[25],"Ketones have been suggested to have significant physiological effects in patients with heart failure. Potential mechanisms for these effects include energy provision for the failing heart and direct protective effects on other organs. Despite the strong physiological rationale, the acute effects of ketone therapy in patients with acute heart failure (AHF) is unclear. AHF is a major healthcare issue, with in-hospital mortality exceeding 10%. Therefore, we propose a vanguard randomized controlled trial to assess the effects of ketone esters in patients with AHF. Sixty patients hospitalized with AHF will be randomized to receive either 25 grams of ketone esters three times per day or a matching placebo for five days, or until death or hospital discharge. We hypothesize that ketone therapy will improve markers of systemic congestion and heart failure symptoms. Primary endpoint will be changes in NT-proBNP levels during therapy. Secondary endpoints will be KCCQ scores, and hemodynamic profile as assessed by echocardiogram. Exploratory endpoints will clinical outcomes including mortality, need for intensive care unit admission, among others.",[511],"Acute Heart Failure","2026-06-03",{"date":492,"type":46},{"date":98,"type":22},{"date":516,"type":22},"2028-03",{"name":52,"class":53},{"id":519,"slug":520,"hasResults":12,"nctId":521,"briefTitle":522,"officialTitle":523,"acronym":524,"eligibilityCriteria":525,"healthyVolunteers":12,"sex":18,"minAge":526,"maxAge":526,"enrollmentInfo":527,"targetDuration":4,"studyType":23,"phases":529,"briefSummary":530,"conditions":531,"keywords":533,"overallStatus":42,"whyStopped":4,"lastUpdateSubmitDate":512,"lastUpdatePostDateStruct":541,"startDateStruct":543,"completionDateStruct":545,"leadSponsor":547,"locationsCount":54},"100624195","phase-2-the-protect-hie-pilot-trial-100624195","NCT07406477","The PROTECT-HIE Pilot Trial","The PROTECT-HIE Pilot Trial: Prophylactic Therapy to Enhance Cardiovascular Treatment in Neonatal Hypoxemic Ischemic Encephalopathy","PROTECT-HIE","Inclusion Criteria:\n\n* Newborns with hypoxemic ischemic encephalopathy (HIE) receiving therapeutic hypothermia (TH).\n\nExclusion Criteria:\n\n1. Congenital abnormality\n2. known contraindication of dobutamine\n\n   * Left ventricular outflow tract dynamic obstruction\n   * Hypersensitivity to dobutamine\n   * Uncorrected tachyarrhythmias or ventricular fibrillation\n3. Newborns who are already started on inotropes at the time of randomization.\n4. Parental refusal to consent to participate","1 Day",{"count":528,"type":22},40,[116],"Some babies experience a lack of oxygen and blood flow around the time of birth. This can lead to a serious condition called hypoxic-ischemic encephalopathy (HIE), which can injure the brain and other organs, including the heart. To reduce brain injury, babies with HIE are treated with therapeutic hypothermia, a standard treatment in which the baby's body temperature is carefully lowered for several days. While cooling helps protect the brain, many babies with HIE still develop heart problems and low blood flow, which may worsen outcomes.\n\nDoctors often use medications to support the heart and circulation in these babies, but there is no clear agreement on which medication works best or when it should be started. One commonly used medication is dobutamine, which helps the heart pump more effectively. Dobutamine is already used in newborn intensive care units when babies show signs of heart weakness, but it is usually started only after problems develop.\n\nThe PROTECT-HIE trial aims to find out whether it is possible and safe to start dobutamine early, before clear signs of heart failure appear, in newborns with HIE who are receiving therapeutic hypothermia. The idea is that early support of the heart may improve blood flow to vital organs, including the brain, and potentially reduce injury.\n\nIn this study, 40 newborns with HIE will take part at a single neonatal intensive care unit. Babies will be randomly assigned to one of two groups. One group will receive a low, preventative dose of dobutamine within the first four hours after cooling begins. The other group will receive a placebo (an inactive fluid that looks the same). Neither the families nor the medical team assessing outcomes will know which treatment the baby received.\n\nThe main goal of this study is to determine feasibility-that is, whether starting dobutamine early during cooling can be done reliably and safely in this setting. Researchers will also collect information on important health outcomes, such as signs of brain injury on MRI, seizures, need for additional heart medications, heart function on ultrasound, recovery of blood markers, urine output, length of hospital stay, and survival.\n\nBecause HIE is an emergency condition and treatment must start very soon after birth, parents will be approached for consent after the baby has been stabilized. This approach is commonly used in neonatal emergency research and has been approved in similar studies.\n\nThe results of this study will help determine whether a larger trial should be done in the future. Ultimately, this research aims to improve care and outcomes for babies affected by HIE by optimizing support for the heart during a critical period after birth.",[532],"Hypoxic-ischemic Encephalopathy (HIE)",[534,535,536,537,538,539,540],"Hypoxic-ischemic encephalopathy","feasibility RCT","neonatal cardiac dysfunction","prophylactic inotrope","therapeutic hypothermia","neonatal HIE","dobutamine",{"date":542,"type":46},"2026-06-05",{"date":544,"type":22},"2026-07-15",{"date":546,"type":22},"2029-04-30",{"name":52,"class":53},{"id":549,"slug":550,"hasResults":12,"nctId":551,"briefTitle":552,"officialTitle":553,"acronym":554,"eligibilityCriteria":555,"healthyVolunteers":17,"sex":373,"minAge":89,"maxAge":556,"enrollmentInfo":557,"targetDuration":4,"studyType":23,"phases":559,"briefSummary":561,"conditions":562,"keywords":4,"overallStatus":75,"whyStopped":4,"lastUpdateSubmitDate":512,"lastUpdatePostDateStruct":564,"startDateStruct":565,"completionDateStruct":567,"leadSponsor":569,"locationsCount":570},"100564195","phase-3-screening-for-prostate-cancer-using-high-resolution-micro-ultrasound-versus-multiparametric-magnetic-resonance-imaging-100564195","NCT06626022","Screening for Prostate Cancer Using High Resolution Micro-ultrasound Versus Multiparametric Magnetic Resonance Imaging.","A Phase 3, Multicenter, International, Non-inferiority, Randomized Clinical Trial Comparing Screening for Prostate Cancer Using High Resolution Micro-ultrasound Versus Multiparametric Magnetic Resonance Imaging (MUSIC-Screen)","MUSIC-Screen","Inclusion Criteria:\n\n1. Male sex;\n2. Age 50-70;\n3. PSA 3-20 and\u002For abnormal DRE;\n4. Biopsy naïve.\n\nExclusion Criteria:\n\n1. Prior personal history of prostate cancer;\n2. Prior prostate imaging using microUS or MRI;\n3. Contraindication to microUS or MRI;\n4. Testosterone replacement therapy within last 12 months; or\n5. Androgen deprivation therapy within last 12 months.","70 Years",{"count":558,"type":22},1284,[560],"PHASE3","The purpose of this study is to compare whether the FDA and Health Canada approved microUS is as effective as the currently used option (MRI) for imaging the prostate gland. Participants will be randomized into two groups to compare the imaging results of the current standard of care MRI and the new microUS. The study is looking to identify the most effective imaging modality to help guide whether you progress to have a prostate biopsy.",[563],"Prostate Cancer Screening",{"date":492,"type":46},{"date":566,"type":46},"2025-05-08",{"date":568,"type":22},"2029-11-30",{"name":52,"class":53},9,{"id":572,"slug":573,"hasResults":12,"nctId":574,"briefTitle":575,"officialTitle":576,"acronym":577,"eligibilityCriteria":578,"healthyVolunteers":12,"sex":18,"minAge":579,"maxAge":4,"enrollmentInfo":580,"targetDuration":4,"studyType":23,"phases":582,"briefSummary":583,"conditions":584,"keywords":586,"overallStatus":75,"whyStopped":4,"lastUpdateSubmitDate":512,"lastUpdatePostDateStruct":591,"startDateStruct":592,"completionDateStruct":594,"leadSponsor":595,"locationsCount":54},"100555678","personalized-anti-inflammatory-fibres-in-ulcerative-colitis-100555678","NCT06515210","Personalized Anti-Inflammatory Fibres in Ulcerative Colitis","Clinical Profiling of Anti-inflammatory Fibre Supplements in Patients With Ulcerative Colitis: Towards Personalized Complementary Strategies.","PAIF-UC","Inclusion Criteria:\n\n* Known diagnosis of ulcerative colitis.\n* Evidence of active disease, defined as either 1) measured FCP \\>100 µg\u002Fg at screening, OR 2) Partial Mayo Scoring Index Assessment for UC ≥2 (adult patients) OR Pediatric UC Activity Index (PUCAI) ≥10 (pediatric patients). Patients who are in clinical remission (Partial Mayo \\\u003C2 or PUCAI \\\u003C10) that have active inflammation (elevated FCP \\>100 µg\u002Fg) would also be eligible, as will patients with active symptoms, regardless of availability of FCP.\n* Tanner stage ≥4 for pediatric patients.\n* Weight \\>40kg.\n* No changes to IBD-related medications in three months prior to study onset (stable therapy, including use of 5-aminosalicylic acid, biologics, and immunosuppressive medications; some minor adjustments allowed, such as increasing dose for weight change, or change to a compatible\u002Fgeneric treatment).\n* Men and women that use adequate contraceptive methods.\n* Able to maintain current lifestyle (diet, exercise, supplements\u002Fmedications, and sleep) throughout study.\n\nExclusion Criteria:\n\n* Inability to provide informed consent.\n* Presence of Crohn disease, IBD unclassified, non-IBD bowel conditions (e.g., celiac), or motility disorder.\n* Presence of abnormal constrictions of the gastrointestinal tract, diseases of the esophagus and\u002For the superior opening of the stomach (cardia), potential or existing intestinal blockage, paralysis of the intestine, megacolon, fecal impaction, inflamed bowel or appendicitis, or have failed to defecate after taking another laxative.\n* History of significant chronic disorders such as severe cardiac disease, malignancy requiring systemic chemotherapy or radiation therapy, significant renal failure, severe pulmonary disease, kidney disorders, diabetes, arthritis, multiple sclerosis, or other immune-mediated conditions requiring systemic therapy.\n* Presence of serious infection (e.g., infectious colitis).\n* Presence of severe anemia, defined as hemoglobin \\\u003C100 g\u002FL or considered clinically significant based on physician discretion.\n* Presence of disease or condition that negatively impacts ability to swallow, which may interfere with intake of supplement.\n* Use of systemic antibiotics for more than a week during two months prior to intervention, or any antibiotic use during the intervention.\n* Use of medications that inhibit peristaltic movement (e.g. opioids, loperamide)\n* Consistent use of topical therapies (e.g., rectal suppositories, enemas) for at least a week, with a resulting improvement in symptoms (defined based on physician discretion).\n* Use of probiotic, prebiotic, or fibre supplements in month prior to intervention or during the course of the trial that are known to affect the gut microbiome (if these are present in foods, such as yogurt or fermented foods, this will be allowed).\n* Chronic use of laxatives, stool softeners, or anti-diarrheal medications.\n* Chronic use of illicit drugs and\u002For excessive alcohol (e.g., average of \\>7 drinks\u002Fweek).\n* Current smoker (cigarettes).\n* History of abdominal surgery, including appendectomy.\n* Pregnancy or intention of the patient to become pregnant during the study period.\n* Breastfeeding.\n* Allergy to any ingredients of investigational products or placebo (i.e., acacia gum, microcrystalline cellulose, or maltodextrin).\n* Unable to maintain high fiber intake through supplementation during intervention.","14 Years",{"count":581,"type":22},69,[25],"The goal of this clinical trial is to determine the clinical effects of two different dietary fibre supplements, acacia gum (AG) and microcrystalline cellulose (MCC), in patients with ulcerative colitis. The main question it aims to answer is: Can the fibre supplements reduce gut inflammation (fecal calprotectin)?\n\nResearchers will compare AG and MCC to a placebo (a look-alike substance that contains no fibre) to see if the fibre supplements improve inflammation in ulcerative colitis.\n\nParticipants will add their assigned fibre supplement or placebo to their usual diet daily for 6 weeks. They will visit the clinic at baseline, week 3, and week 6 to provide samples (stool, blood) and complete various questionnaires.",[585],"Ulcerative Colitis",[587,588,589,590],"inflammatory bowel disease","ulcerative colitis","dietary fibre","gut microbiome",{"date":542,"type":46},{"date":593,"type":46},"2025-06-03",{"date":168,"type":22},{"name":52,"class":53},{"id":597,"slug":598,"hasResults":12,"nctId":599,"briefTitle":600,"officialTitle":601,"acronym":4,"eligibilityCriteria":602,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":603,"enrollmentInfo":604,"targetDuration":4,"studyType":23,"phases":606,"briefSummary":607,"conditions":608,"keywords":610,"overallStatus":75,"whyStopped":4,"lastUpdateSubmitDate":613,"lastUpdatePostDateStruct":614,"startDateStruct":615,"completionDateStruct":616,"leadSponsor":618,"locationsCount":54},"100628910","reaching-the-unreached-home-based-telerehabilitation-for-stroke-survivors-100628910","NCT07467785","Reaching the Unreached: Home-Based Telerehabilitation for Stroke Survivors","Reaching the Unreached: Randomized Trial of Home-Based Telerehabilitation for Stroke Without Outpatient Care","Inclusion Criteria:\n\n1. Not currently referred to, or participating in, upper extremity outpatient rehabilitation.\n2. A confirmed stroke diagnosis (ischemic or hemorrhagic)\n3. Have moderate-to-severe upper limb impairment\n4. Live at home\n5. Have access to internet and appropriate devices to have a virtual assessment with clinicians.\n6. ≥ 18 years of age\n\nExclusion Criteria:\n\n1. Referred to or currently participating in upper extremity outpatient rehabilitation.\n2. Severe cognitive, communication, or medical comorbidities that would preclude safe home-based exercise\n3. Don't have access to internet and appropriate devices to have a virtual assessment with clinicians.\n4. \\\u003C 18 years of age","80 Years",{"count":605,"type":22},200,[25],"After a stroke, many people have trouble using their arms and hands. This can make daily tasks-like eating, dressing, or writing-very hard. In Alberta, especially in small towns and rural areas, many stroke survivors go home from the hospital without being referred to rehabilitation. As a result, they miss out on therapy that could help them get better.\n\nThis project will test a new way to bring rehabilitation directly into people's homes using telerehabilitation. We will work with 200 stroke survivors across Alberta who did not get regular outpatient rehab. Participants will use the clinically validated Tenzr system-a set of fun, game-like exercises with wearable sensors. Therapists will check in and guide them remotely.\n\nWhen participants are enrolled in the study, they will be randomized (1:1) into two groups. The Immediate group will receive 8 weeks of home-based telerehabilitation using the Tenzr platform immediately after baseline, while the Delayed group will receive 8 weeks of observation (usual care) followed by 8 weeks of the same telerehabilitation intervention. Everyone in the study will be tested at the baseline, 8 weeks, and 16 weeks. At 16 weeks, we will also interview them to gather their feedback on the telerehabilitation. We want to learn if this program helps people improve arm and hand movement, if it's easy to use, and if people like it. We also want to see if it could be offered more widely across Alberta in the future.\n\nThe goal is to give more people access to stroke rehabilitation, no matter where they live.",[609],"Stroke",[162,611,612],"telerehabilitation","neurorecovery","2026-06-02",{"date":512,"type":46},{"date":613,"type":46},{"date":617,"type":22},"2028-08",{"name":52,"class":53},{"id":620,"slug":621,"hasResults":12,"nctId":622,"briefTitle":623,"officialTitle":624,"acronym":625,"eligibilityCriteria":626,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":627,"targetDuration":4,"studyType":23,"phases":629,"briefSummary":630,"conditions":631,"keywords":634,"overallStatus":75,"whyStopped":4,"lastUpdateSubmitDate":613,"lastUpdatePostDateStruct":639,"startDateStruct":640,"completionDateStruct":642,"leadSponsor":644,"locationsCount":474},"100623826","phase-1-fecal-microbiota-transplantation-in-an-expanded-ulcerative-colitis-population-100623826","NCT07401680","Fecal Microbiota Transplantation in an Expanded Ulcerative Colitis Population","A Multi-centre, Randomised Controlled Trial Comparing Fecal Microbiota Transplantation to Placebo in an Expanded Ulcerative Colitis Population: a Feasibility Study (FRONTIER-UC)","FRONTIER-UC","Inclusion Criteria:\n\n1. 18 years of age or older\n2. Able to provide informed consent\n3. Established UC diagnosis through standard endoscopic and histologic criteria\n4. Active UC\n5. Use of effective contraception method for women of childbearing potential for at least 4 weeks prior to receiving study treatment and for the duration of the trial\n6. Willing and able to comply with all required study procedures\n\nExclusion Criteria:\n\n1. Severe UC requiring hospitalization\n2. Crohn's disease or indeterminate colitis\n3. Irritable bowel syndrome\n4. Intestinal infection within 4 weeks of enrollment\n5. Evidence of toxic megacolon or gastrointestinal perforation on imaging\n6. Planned colectomy\n7. Abdominal surgery within 60 days of enrollment\n8. Neutropenia with absolute neutrophil count \\\u003C0.5 x 109\u002FL\n9. Peripheral white blood cell count \\> 35.0 x 109\u002FL and fever (\\>38C)\n10. Planned or actively taking another investigational product\n11. Uncontrolled medical conditions such as psychiatric disorders or substance abuse\n12. Severe underlying disease such that the patient is not expected to survive for at least 30 days\n13. Pregnancy or breastfeeding\n14. Unwilling to discontinue non-dietary probiotic\n15. Antibiotic use 30 days prior to enrollment or anticipated need for systemic antibiotic use during study\n16. FMT for any reason within 6 months of enrollment\n17. Investigator's judgement that enrolment is not in the best interest of the patient",{"count":628,"type":22},85,[115],"This is a multi-centre, randomised controlled trial comparing fecal microbiota transplantation to placebo in an expanded ulcerative colitis population: a feasibility study (FRONTIER-UC) to determine whether a full-scale randomized controlled trial (RCT) to investigate fecal microbiota transplantation (FMT) in ulcerative colitis (UC) is feasible.",[585,632,633],"Inflammatory Bowel Diseases","Clostridioides Difficile Infection",[635,636,637,638],"Fecal microbiota transplantation","FMT","Lyophilized fecal microbiota transplantation","LFMT",{"date":492,"type":46},{"date":641,"type":46},"2026-03-01",{"date":643,"type":22},"2028-12-01",{"name":52,"class":53},{"id":646,"slug":647,"hasResults":12,"nctId":648,"briefTitle":649,"officialTitle":650,"acronym":4,"eligibilityCriteria":651,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":652,"targetDuration":4,"studyType":23,"phases":654,"briefSummary":656,"conditions":657,"keywords":659,"overallStatus":75,"whyStopped":4,"lastUpdateSubmitDate":613,"lastUpdatePostDateStruct":663,"startDateStruct":664,"completionDateStruct":666,"leadSponsor":668,"locationsCount":54},"100603743","phase-4-sotatercept-in-pulmonary-arterial-hypertension-100603743","NCT07140484","Sotatercept in Pulmonary Arterial Hypertension","A Single-arm, Open-label Phase IV Study to Evaluate the Effectiveness of Sotatercept in Improving Pulmonary Vascular Recruitment in Patients With Pulmonary Arterial Hypertension (PAH)","Eligible participants must meet all of the following inclusion criteria to be enrolled in the study:\n\n1. Age ≥ 18 years.\n2. Documented diagnostic right heart catheterization (RHC) at any time prior to screening confirming the diagnosis of PAH Group 1 in any of the following subtypes:\n\n   * Idiopathic PAH\n   * Heritable PAH\n   * Drug\u002Ftoxin-induced PAH\n   * PAH associated with CTD\n   * PAH associated with simple, congenital systemic-to-pulmonary shunts at least 1 year following repair.\n3. Symptomatic PAH classified as WHO FC II or III.\n4. On stable doses of ≥2 background PAH therapies for at least 60 days prior to screening; for infusion prostacyclins, dose adjustment within 10% of the optimal dose is allowed per medical practice. Patients on 1 background PAH therapy are eligible if there is documented intolerance or contraindication to use of the other 2 classes (e.g. liver enzyme elevation while taking an ERA).\n5. Females of childbearing potential must:\n\n   * Have a negative urine or serum pregnancy tests as verified by the investigator prior to starting study therapy.\n   * If sexually active, have used, and agree to use highly effective contraception without interruption during the study (including dose interruptions), and for 16 weeks (112 days) after discontinuation of study treatment.\n   * Refrain from breastfeeding a child or donating blood, eggs, or ovum for the duration of the study and for at least 16 weeks (112 days) after the last dose of study treatment.\n6. Male participants must:\n\n   * Agree to use a condom, defined as a male latex condom or nonlatex condom NOT made out of natural (animal) membrane (e.g., polyurethane), during sexual contact with a pregnant female or a female of childbearing potential while participating in the study, during dose interruptions and for at least 16 weeks (112 days) following investigational product discontinuation, even if he has undergone a successful vasectomy.\n   * Refrain from donating blood or sperm for the duration of the study and for 16 weeks (112 days) after the last dose of study treatment\n7. Ability to adhere to study visit schedule and understand and comply with all protocol requirements.\n8. Ability to understand and provide written informed consent.\n\nExclusion Criteria\n\n1. 1\\. Diagnosis of pulmonary hypertension WHO Groups 2, 3, 4, or 5\n2. Musculoskeletal limitation that precludes participation in cycle ergometry\n3. Resting oxygen saturation \\\u003C 88%. (Note: patients on oxygen can be included in the study if they can maintain a resting saturation of ≥ 88 % after 3 minutes off oxygen).\n4. Diagnosis of the following PAH Group 1 subtypes: human immunodeficiency virus (HIV)-associated PAH and PAH associated with portal hypertension, schistosomiasis-associated PAH and pulmonary veno-occlusive disease.\n5. Hemoglobin (Hgb) at screening above the gender-specific upper limit of normal (ULN), per local laboratory test.\n6. Baseline platelet count \\\u003C 50,000\u002Fmm3 (\\\u003C 50.0 × 109\u002FL) in the enrollment period.\n7. Uncontrolled systemic hypertension as evidenced by sitting systolic blood pressure \\> 160 mmHg or sitting diastolic blood pressure \\> 100 mmHg during a screening visit after a period of rest.\n8. Baseline systolic blood pressure \\\u003C 90 mmHg at screening.\n9. Pregnant or breastfeeding women.\n10. Any of the following clinical laboratory values at the screening visit:\n\n    * Estimated glomerular filtration rate (eGFR) \\\u003C 30 mL\u002Fmin\u002Fm2 (as defined by the Modification of Diet in Renal Disease \\[MDRD\\] equation)\n    * Serum alanine aminotransferase, aspartate aminotransferase, or total bilirubin levels \\> 3 × ULN (bilirubin criterion waived if there is a documented history of Gilbert's syndrome).\n11. Currently enrolled in or have completed any other investigational product study within 30 days for small-molecule drugs or within 5 half-lives for biologics prior to the date of signed informed consent.\n12. History of full pneumonectomy.\n13. Pulmonary function test (PFT) values of forced vital capacity (FVC) \\\u003C 60% predicted and\u002For FEV1\u002FFVC \\\u003C lower limit of normal at the screening visit or within 6 months prior to the screening visit.\n14. Smoking history of ≥ 20 pack-years or any tobacco smoking or vaping within the previous 3 months.\n15. Body mass index ≥ 40 kg\u002Fm2.\n16. Planned initiation of an exercise program for cardiopulmonary rehabilitation during the study (participants who are stable in the maintenance phase of a program and who will continue for the duration of the study are eligible).\n17. Known history of portal hypertension or chronic liver disease, including hepatitis B and\u002For hepatitis C (with evidence of recent infection and\u002For active virus replication), defined as mild to severe hepatic impairment (Child-Pugh Class A-C).\n18. History of restrictive, constrictive, or congestive cardiomyopathy.\n19. History of atrial septostomy within 180 days prior to the screening visit.\n20. Electrocardiogram (ECG) with Fridericia's corrected QT interval (QTcF) \\> 500 ms during the Screening Period\n21. Personal or family history of long QT syndrome (LQTS) or sudden cardiac death.\n22. Left ventricular ejection fraction \\\u003C 45% on historical echocardiogram within 6 months prior to the screening visit.\n23. Any symptomatic coronary disease events (prior myocardial infarction, percutaneous coronary intervention, coronary artery bypass graft surgery, or cardiac anginal chest pain) within 6 months prior to the screening visit. Note: Anginal pain can be ignored as an exclusion criterion if coronary angiography shows no obstructions.\n24. Cerebrovascular accident within 3 months prior to the Screening Visit.\n25. Significant mitral or aortic valve dysfunction (greater than moderate mitral regurgitation or aortic regurgitation, or greater than mild mitral stenosis or aortic stenosis).\n26. Received intravenous inotropes (e.g., dobutamine, dopamine, norepinephrine, vasopressin) within 30 days prior to the screening visit.\n27. Known hypersensitivity to sotatercept or to any ingredient in the formulation or component of the container.",{"count":653,"type":22},27,[655],"PHASE4","The goal of this clinical trial is to determine whether sotatercept is effective in improving diffusing capacity in patients with pulmonary arterial hypertension.\n\nParticipants will be asked to:\n\n* Take Sotatercept every 21 days (±3 days)\n* Each participant will be enrolled in the study for 29 Weeks\n* Visit the clinic 18 times\n* Have a physical exam\n* Perform assessments of lung function and exercise tests\n* Have an ultrasound of their heart\n* Have blood draws done at regular intervals\n\nThe main objectives of the study are:\n\nPrimary objective: To assess whether sotatercept will improve recruitment of diffusing membrane capacity (DM) with exercise.\n\nSecondary objective: To identify components of the diffusing capacity that respond to treatment with sotatercept in pulmonary arterial hypertension.",[658],"Pulmonary Artery Hypertension",[660,661,662],"diffusing capacity","membrane diffusing capacity","pulmonary capillary blood volume",{"date":492,"type":46},{"date":665,"type":46},"2025-10-06",{"date":667,"type":22},"2030-01-01",{"name":52,"class":53},""]